Iqirvo (Elafibranor)

Elafibranor is a dual agonist of the nuclear receptors PPARα and PPARδ. By activating these receptors, it modulates genes that control fatty‑acid oxidation, inflammation, and fibrotic processes, thereby improving lipid metabolism and reducing hepatic inflammation and fibrosis.

The dosing regimen for Iqirvo is determined by the prescribing physician based on the individual patient's clinical condition, laboratory results, and response to therapy. No fixed dose is provided here; the prescriber will set the appropriate dose.

Safety data for Elafibranor during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the Iqirvo product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for primary biliary cholangitis is ursodeoxycholic acid, which works by improving bile flow. Iqirvo, as a PPARα/δ agonist, targets metabolic and inflammatory pathways rather than bile composition, offering a complementary mechanism for patients who do not respond sufficiently to ursodeoxycholic acid.

Iqirvo tablets should be stored at room temperature, below 25 °C, in the original blister pack. Keep the product away from excess moisture, heat and direct sunlight to maintain stability and potency.

Iqirvo is administered orally as a tablet. Patients should swallow the tablet whole with water, typically once daily, unless otherwise directed by their healthcare provider.

Serious risks include significant elevations in liver enzymes, which may indicate liver injury, severe allergic reactions such as anaphylaxis, and pancreatitis. Patients should promptly report symptoms like jaundice, rash, swelling, or persistent abdominal pain to their physician.

Iqirvo should be avoided in patients with known hypersensitivity to Elafibranor or any excipients, in those with severe hepatic impairment, and in individuals for whom the prescriber determines that the risk–benefit profile is unfavorable, such as certain pregnant or lactating women.